Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q28kexhibit991.htm EX-99.1 Document Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update August 5, 2026 • Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment f
HC Wainwright raised its Arcus Biosciences (RCUS) price forecast 33%, from $32 to $45, citing Arcus’ push to position casdatifan in first-line clear cell renal cell carcinoma. Arcus said it is enrolling a Phase 1/1b ARC-20 cohort to support a Phase 3 start by year-end 2026. The model assumes about $2.2B peak unadjusted 1L revenues.
Jaen Juan C. (President) sold 68,569 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $29.63 ($28.61–$30.05, $2.03M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning RCUS (Arcus Biosciences, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RCUS coverage spans financial news, insider activity and earnings.
In the last 30 days, RCUS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($574K). The most active reporter was Jaen Juan C., President, with 2 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The filing adds time-specific catalysts (milestone cash, multiple ARC-20 readouts, and PEAK-1 enrollment acceleration) that can re-rate casdatifan probability-weighted value.
The PT hike is driven by expanded modeled revenue assumptions for casdatifan in broad 1L ccRCC, plus a plan to generate Phase 3-enabling data via ARC-20 enrollment.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, with no new operating or regulatory catalyst disclosed.
Routine 10b5-1 insider selling provides limited signal; it may slightly affect sentiment but is not a fundamental catalyst by itself.
Routine shareholder-meeting outcomes; no new operating, financial, or regulatory catalyst disclosed beyond governance vote tallies.
alphai scores every news story that mentions RCUS with an AI model for sentiment and relevance, and aggregates insider trades from Arcus Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q28kexhibit991.htm EX-99.1 Document Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update August 5, 2026 • Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment f
7 min readHC Wainwright raised its Arcus Biosciences (RCUS) price forecast 33%, from $32 to $45, citing Arcus’ push to position casdatifan in first-line clear cell renal cell carcinoma. Arcus said it is enrolling a Phase 1/1b ARC-20 cohort to support a Phase 3 start by year-end 2026. The model assumes about $2.2B peak unadjusted 1L revenues.
4 min readJaen Juan C. (President) sold 68,569 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $29.63 ($28.61–$30.05, $2.03M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
2 min readJaen Juan C. (President) sold 31,431 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $27.92 ($27.03–$29.66, $0.88M total) across 4 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min readArcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rcus-20260611 false 0001724521 0001724521 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua
2 min readArcus Biosciences CAO Alexander Azoy sold 2,562 shares of RCUS on June 1 at an average $25.77, for about $66,022.74, under a Rule 10b5-1 plan, according to an SEC filing. Afterward, he held 39,581 shares. RCUS traded around $25.74 on Monday. The company reported May 5 quarterly EPS of -$1.02 and revenue of $17.0M.
4 min readAzoy Alexander (Chief Accounting Officer) sold 2,562 shares of Arcus Biosciences, Inc. (RCUS) at $25.77 on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readArcus Biosciences (RCUS) stock rose 7.8% on impressive volume due to investor confidence in its pipeline candidates for cancer. Despite this, the company is expected to post a quarterly loss, and the consensus EPS estimate has remained unchanged, suggesting that sustained strength might depend on future earnings estimate revisions. Investors are advised to monitor RCUS and consider its Zacks Rank #3 (Hold) status.
4 min readArcus Biosciences (RCUS) stock has reached a new 52-week high at $21.03, reflecting strong investor confidence and market momentum with a 67.57% increase over the past year and 132.12% over six months. Despite holding more cash than debt, the company is rapidly burning through cash, with a negative EBITDA of $365 million. Recent developments include an amended loan agreement and varying analyst ratings, with Goldman Sachs upgrading to Buy and Morgan Stanley downgrading to Equalweight.
4 min readArcus Biosciences (RCUS) shares fell by 11.2% in recent trading, indicating market volatility for the biotechnology company focused on cancer immunotherapies. The company faces significant financial challenges, with negative operating and net margins and declining revenue growth, alongside moderate balance sheet strength but an Altman Z-Score suggesting potential bankruptcy risk. Despite cautious optimism from analysts and a positive trend in moving averages, the stock carries risks including high volatility and insider selling.
3 min read
